Novartis AG (SWX:NOVN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
103.76
-0.58 (-0.56%)
Oct 17, 2025, 4:02 PM CET
-0.56%
Market Cap201.99B
Revenue (ttm)43.89B
Net Income (ttm)10.86B
Shares Out1.94B
EPS (ttm)5.45
PE Ratio19.15
Forward PE14.69
Dividend3.50 (3.35%)
Ex-Dividend DateMar 11, 2025
Volume1,531,324
Average Volume2,548,249
Open103.74
Previous Close104.34
Day's Range102.60 - 103.92
52-Week Range81.10 - 106.88
Beta0.57
RSI55.95
Earnings DateOct 28, 2025

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]

Sector Healthcare
Founded 1996
Employees 75,883
Stock Exchange SIX Swiss Exchange
Ticker Symbol NOVN
Full Company Profile

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial numbers in USD Financial Statements

News

Novartis (NVS) Gains EMA Support for Scemblix in Treating Chronic Myeloid Leukemia

Novartis (NVS) Gains EMA Support for Scemblix in Treating Chronic Myeloid Leukemia

2 hours ago - GuruFocus

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

Basel, October 17, 2025 – Novartis today announced results from the five-year analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that demonstrated a sustained benefit at a median...

2 hours ago - GlobeNewsWire

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

Basel, October 17, 2025 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended ...

3 hours ago - GlobeNewsWire

Novartis Reports Positive Fabhalta Results In IgAN

Novartis Reports Positive Fabhalta Results In IgAN

20 hours ago - GuruFocus

Novartis: Assessing The Impact Of Entresto Generics

Entresto generics have finally arrived in the U.S. in July, and approximately 9% of Novartis' revenue will be impacted. Learn more about NVS stock here.

21 hours ago - Seeking Alpha

Novartis (NVS) Shows Promising Phase III Results for IgA Nephropathy Treatment

Novartis (NVS) Shows Promising Phase III Results for IgA Nephropathy Treatment

1 day ago - GuruFocus

Novartis' Fabhalta slows progression of rare kidney disease in trial

Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial.

1 day ago - Reuters

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

Basel, October 16, 2025 – Novartis today announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta® (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta,...

1 day ago - GlobeNewsWire

The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne

SAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.

8 days ago - Nasdaq

Top Stock Reports for SAP, Novartis & Philip Morris

SAP, Novartis and Philip Morris headline today's top Zacks reports, each showing strong momentum and strategic growth drivers despite industry headwinds.

8 days ago - Nasdaq

3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal

Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.

9 days ago - Nasdaq

Novartis (NVO) Streamlines Operations with Layoffs in the US

Novartis (NVO) Streamlines Operations with Layoffs in the US

9 days ago - GuruFocus

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

10 days ago - Seeking Alpha

3 Reasons Growth Investors Will Love Novartis (NVS)

Novartis (NVS) could produce exceptional returns because of its solid growth attributes.

10 days ago - Nasdaq

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

11 days ago - Nasdaq

NVS Named Top 10 SAFE International Dividend Stock

Novartis (Symbol: NVS) has been named to the Dividend Channel ''International S.A.F.E. 10'' list, signifying an international stock with above-average ''DividendRank'' statistics including a strong 3....

11 days ago - Nasdaq

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

15 days ago - Nasdaq

Swiss pharma companies eye follow up to Pfizer-US pricing deal, business lobby says

GENEVA (Reuters) -Swiss drugmakers could strike their own deals with the U.S. after President Donald Trump's push to lower prescription drug prices led to an accord with Pfizer in exchange for tariff ...

15 days ago - Yahoo

Big pharma is at war with the UK, and the government can’t back down now | Nick Dearden

The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain This year so far, some of the biggest pharmaceutical corporations in the worl...

16 days ago - The Guardian

FDA Approves Novartis' Rhapsido As First BTKi Oral Therapy For Chronic Spontaneous Urticaria

(RTTNews) - Novartis (NVS) announced that the U.S. Food and Drug Administration has approved Rhapsido (remibrutinib) as an oral treatment for adults with chronic spontaneous urticaria or CSU who conti...

16 days ago - Nasdaq

Novartis (NVS) Gains FDA Approval for Innovative CSU Treatment

Novartis (NVS) Gains FDA Approval for Innovative CSU Treatment

16 days ago - GuruFocus

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with d...

16 days ago - PRNewsWire